Precigen, Inc. (NASDAQ:PGEN) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Precigen, Inc. (NASDAQ:PGEN - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the five brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $7.00.

A number of brokerages have recently commented on PGEN. JMP Securities cut their price objective on shares of Precigen from $14.00 to $7.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 15th. HC Wainwright reiterated a "buy" rating and issued a $4.00 price target on shares of Precigen in a research note on Friday, November 15th.

Precigen Stock Performance

NASDAQ PGEN traded up $0.02 during trading on Friday, hitting $0.93. The stock had a trading volume of 382,864 shares, compared to its average volume of 912,169. Precigen has a 12 month low of $0.77 and a 12 month high of $1.93. The company's 50-day moving average price is $0.89 and its two-hundred day moving average price is $1.21. The company has a market capitalization of $272.37 million, a PE ratio of -1.69 and a beta of 1.68.

Institutional Investors Weigh In On Precigen

Large investors have recently made changes to their positions in the stock. Iridian Asset Management LLC CT raised its position in Precigen by 82.5% during the third quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company's stock worth $3,576,000 after acquiring an additional 1,706,815 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Precigen by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 6,768,234 shares of the biotechnology company's stock valued at $9,814,000 after purchasing an additional 19,875 shares during the period. Cetera Advisors LLC bought a new stake in shares of Precigen in the 1st quarter valued at about $367,000. Renaissance Technologies LLC lifted its stake in Precigen by 12.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,182,690 shares of the biotechnology company's stock valued at $1,869,000 after purchasing an additional 130,500 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in Precigen by 4.8% during the second quarter. Bank of New York Mellon Corp now owns 421,788 shares of the biotechnology company's stock worth $666,000 after purchasing an additional 19,301 shares during the period. Institutional investors and hedge funds own 33.51% of the company's stock.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.